Micro-ultrasound-Guided Focal Laser Ablation for Intermediate-Risk Prostate Cancer: Safety & Effectiveness

This clinical research study is intended to show that Micro-Ultrasound Guided Focal Laser Ablation (MicroUSgFLA) is a safe procedure that can significantly postpone or eliminate the need for patients with intermediate-Risk prostate cancer (PCa) to undergo a definitive treatment (i.e., Radical Prostatectomy or Radiation Therapy) for their disease.

Trial Details

NCT ID
NCT07339943
Phase
NA
Sponsor
University Health Network, Toronto
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • 6 month, prospective, interventional single-arm safety and effectiveness study
  • The TRANBERG|CLS Thermal therapy
Locations (sample)
  • Toronto, Ontario, Canada|43.65333,-79.38389

Key Eligibility Criteria

  • Men 40-80 years of age.
  • Histologically-proven intermediate-risk PCa (Gleason score 7, primary grade ≤ 4).
  • PCa clinical stage T1c or T2.
  • MRI/MicroUS site suspicious for cancer or cancer mapped to one prostate lobe.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →